成纤维细胞生长因子受体在糖脂代谢性疾病中的研究进展

诗曼 金(河北省承德市承德医学院附属医院，中国)
国民 张(河北省承德市承德医学院附属医院，中国)
聂平 王(河北省承德市承德医学院附属医院，中国)

摘要

成纤维细胞因子生长受体（Fibroblast growth factor receptors, FGFRs）是一种高亲和力酪氨酸激酶受体（Tyrosine kinasereceptor，RTK），它与成纤维细胞生长因子（Fibroblast growth factors，FGFs）配体相结合进行信号传导，参与机体的胚胎发育、细胞增殖和迁移、血管生成、伤口愈合等关键过程。糖脂代谢性疾病，包括糖尿病、肥胖、非酒精性脂肪性肝病、心血管疾病等。随着中国人口老龄化及人民生活方式的改变，糖脂代谢性疾病的患病率逐年上升。近年来研究发现FGFRs在糖脂代谢紊乱的调节中发挥着重要作用。论文就FGFRs及其在主要糖脂代谢性疾病中的研究进展进行了介绍。

关键词

成纤维细胞生长因子受体；糖脂代谢性疾病；非酒精性脂肪性肝病

参考

Itoh N, Ornitz D M. Functional evolutionary history of the mouse Fgf gene family [J]. Dev Dyn, 2008,237(1):18-27.

Xie Y, Su N, Yang J, et al. FGF/FGFR signaling in health and disease [J]. Signal Transduct Target Ther,2020,5(1):181.

Mohammadi M, Olsen S K, Ibrahimi O A. Structural basis for fibroblast growth factor receptor activation [J]. Cytokine Growth Factor Rev,2005,16(2):107-137.

Itoh N, Ornitz D M. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease [J]. J Biochem, 2011,149(2):121-130.

Faul C. Cardiac actions of fibroblast growth factor 23 [J]. Bone, 2017(100):69-79.

Li X. The FGF metabolic axis [J]. Front Med, 2019,13(5):511-530.

Chen L, Fu L, Sun J, et al. Structural basis for FGF hormone signalling [J]. Nature,2023,618(7966):862-870.

Szybowska P, Kostas M, Wesche J, et al. Negative Regulation of FGFR (Fibroblast Growth Factor Receptor) Signaling [J]. Cells,2021,10(6).

Dailey L, Ambrosetti D, Mansukhani A, et al. Mechanisms underlying differential responses to FGF signaling [J]. Cytokine Growth Factor Rev,2005,16(2):233-247.

Ying L, Wang L, Guo K, et al. Paracrine FGFs target skeletal muscle to exert potent anti-hyperglycemic effects [J]. Nat Commun, 2021,12(1):7256.

Grabner A, Schramm K, Silswal N, et al. FGF23/FGFR4-mediated left ventricular hypertrophy is reversible [J]. Sci Rep, 2017,7(1):1993.

Pan J A, Lin H, Yu J Y, et al. MiR-21-3p Inhibits Adipose Browning by Targeting FGFR1 and Aggravates Atrial Fibrosis in Diabetes [J]. Oxid Med Cell Longev, 2021, 2021:9987219.

Yanucil C, Kentrup D, Li X, et al. FGF21-FGFR4 signaling in cardiac myocytes promotes concentric cardiac hypertrophy in mouse models of diabetes [J]. Sci Rep, 2022,12(1):7326.

Samsu N. Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment [J]. Biomed Res Int, 2021,2021:1497449.

Cheng M F, Chen L J, Wang M C, et al. Decrease of FGF receptor (FGFR) and interstitial fibrosis in the kidney of streptozotocin-induced diabetic rats [J]. Horm Metab Res,2014,46(1):1-7.

Zhou X, Zhang Y, Wang N. Regulation and Potential Biological Role of Fibroblast Growth Factor 21 in Chronic Kidney Disease [J]. Front Physiol, 2021,12:764503.

Smith E R, Holt S G, Hewitson T D. FGF23 activates injury-primed renal fibroblasts via FGFR4-dependent signalling and enhancement of TGF-β autoinduction [J]. Int J Biochem Cell Biol, 2017(92):63-78.

Taylor A, Yanucil C, Musgrove J, et al. FGFR4 does not contribute to progression of chronic kidney disease [J]. Sci Rep, 2019,9(1):14023.

Jeon J Y, Choi S E, Ha E S, et al. Association between insulin resistance and impairment of FGF21 signal transduction in skeletal muscles [J]. Endocrine, 2016,53(1):97-106.

王文茜,开悦,刘虎,等.高脂饮食对小鼠不同组织中成纤维细胞生长因子2 1及其受体表达的影响[J].新乡医学院学报,2020,37(4):318-322.

Chakravarthy M V, Neuschwander-Tetri B A. The metabolic basis of nonalcoholic steatohepatitis [J]. Endocrinol Diabetes Metab, 2020,3(4):e00112.

Younossi Z M, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis [J]. J Hepatol, 2019,71(4):793-801.

Huang X, Yang C, Luo Y, et al. FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver [J]. Diabetes,2007,56(10):2501-2510.

Song L, Wang L, Hou Y, et al. FGF4 protects the liver from nonalcoholic fatty liver disease by activating the AMPactivated protein kinase-Caspase 6 signal axis [J].Hepatology, 2022,76(4):1105-1120.

Zhang F, Yu L, Lin X, et al. Minireview: Roles of Fibroblast Growth Factors 19 and 21 in Metabolic Regulation and Chronic Diseases [J]. Mol Endocrinol, 2015,29(10):1400-1413.

Qi M, Xin S. FGF signaling contributes to atherosclerosis by enhancing the inflammatory response in vascular smooth muscle cells [J]. Mol Med Rep, 2019,20(1):162-170.

Mao Y, Liu X, Song Y, et al. VEGF-A/VEGFR-2 and FGF-2/FGFR-1 but not PDGF-BB/PDGFR-β play important roles in promoting immature and inflammatory intraplaque angiogenesis [J]. PLoS One, 2018,13(8):e0201395.

DOI: http://dx.doi.org/10.12345/yzlcyxzz.v7i1.15597